Standard Interpretations - Table of Contents|
| Standard Number:||1910.1030; 1910.1030(b)|
|This letter constitutes OSHA's interpretation only of the requirements discussed and may not be applicable to any situation not delineated within the original correspondence.|
Plasma Protein Therapeutics Association (PPTA) is a trade association representing the major commercial processors of plasma derivatives. PPTA requests that, "OSHA limit its interpretations that include plasma derivatives in the BPS definition of ‘blood,' and provide an exemption from the standard for FDA-approved, US-licensed plasma derivatives that have undergone viral inactivation and/or removal processes."Your request deals only with plasma derivatives after they have been fully processed, such as when they are used in a health care facility. As you know, the Bloodborne Pathogens Standard is intended to protect workers in diverse settings from occupational exposure to blood and other potentially infectious materials (OPIM). The standard's definition of blood includes, "human blood, human blood components, and products made from human blood" [29 CFR §1910.1030(b)]. Clearly, because plasma derivatives are derived from human blood, they would be considered to be "products made from human blood"; plasma derivatives are covered by the standard.
|Standard Interpretations - Table of Contents|
The Department of Labor does not endorse, takes no responsibility for, and exercises no control over the linked organization or its views, or contents, nor does it vouch for the accuracy or accessibility of the information contained on the destination server. The Department of Labor also cannot authorize the use of copyrighted materials contained in linked Web sites. Users must request such authorization from the sponsor of the linked Web site. Thank you for visiting our site. Please click the button below to continue.